Literature DB >> 19105569

Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays.

Mona Shehata1, Judith Weidenhofer, Keerthi Thamotharampillai, Jayne R Hardy, Jennifer A Byrne.   

Abstract

The tumor protein D52 gene is increasingly recognized to be overexpressed in different cancer types, frequently through gain of the corresponding locus at chromosome 8q21.13. This review summarizes the literature identifying D52 overexpression and/or gene amplification in different cancers, as well as recent publications directly analyzing D52 functions. Since D52 overexpression is increasingly being identified in tumors of different cellular origins, this is likely to perturb fundamental cell properties common to different cell types. Furthermore,since increased D52 expression occurs at different stages of tumorigenesis and progression, this could contribute to these processes through multiple mechanisms. Although functions are beginning to emerge from targeted studies, the pathways through which D52 overexpression contributes to cell transformation and the molecular interactions required remain undefined. In summary, while targeting D52 overexpression could provide therapeutic benefits in many cancer types, this will require an improved understanding of D52's cellular and molecular functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19105569     DOI: 10.1615/critrevoncog.v14.i1.30

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  11 in total

1.  TPD52 expression increases neutral lipid storage within cultured cells.

Authors:  Alvin Kamili; Nuruliza Roslan; Sarah Frost; Laurence C Cantrill; Dongwei Wang; Austin Della-Franca; Robert K Bright; Guy E Groblewski; Beate K Straub; Andrew J Hoy; Yuyan Chen; Jennifer A Byrne
Journal:  J Cell Sci       Date:  2015-07-16       Impact factor: 5.285

2.  Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Huining Kang; Carla S Wilson; Richard C Harvey; I-Ming Chen; Maurice H Murphy; Susan R Atlas; Edward J Bedrick; Meenakshi Devidas; Andrew J Carroll; Blaine W Robinson; Ronald W Stam; Maria G Valsecchi; Rob Pieters; Nyla A Heerema; Joanne M Hilden; Carolyn A Felix; Gregory H Reaman; Bruce Camitta; Naomi Winick; William L Carroll; ZoAnn E Dreyer; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

3.  Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening.

Authors:  Hamideh Shahheydari; Sarah Frost; Brian J Smith; Guy E Groblewski; Yuyan Chen; Jennifer A Byrne
Journal:  Mol Biol Rep       Date:  2014-03-07       Impact factor: 2.316

4.  Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.

Authors:  Jennifer A Byrne; Yuyan Chen; Nancy Martin La Rotta; Gregory B Peters
Journal:  Genes Cancer       Date:  2012-02

Review 5.  Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Authors:  Jennifer A Byrne; Sarah Frost; Yuyan Chen; Robert K Bright
Journal:  Tumour Biol       Date:  2014-05-06

6.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

7.  Tumor protein D52 represents a negative regulator of ATM protein levels.

Authors:  Yuyan Chen; Alvin Kamili; Jayne R Hardy; Guy E Groblewski; Kum Kum Khanna; Jennifer A Byrne
Journal:  Cell Cycle       Date:  2013-08-21       Impact factor: 4.534

8.  Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.

Authors:  Jennifer D Bright; Heather N Schultz; Jennifer A Byrne; Robert K Bright
Journal:  Oncoimmunology       Date:  2013-05-21       Impact factor: 8.110

9.  Star-PAP regulates tumor protein D52 through modulating miR-449a/34a in breast cancer.

Authors:  Aizhu Duan; Lingmei Kong; Tao An; Hongyu Zhou; Chunlei Yu; Yan Li
Journal:  Biol Open       Date:  2019-11-06       Impact factor: 2.422

10.  The four-transmembrane protein MAL2 and tumor protein D52 (TPD52) are highly expressed in colorectal cancer and correlated with poor prognosis.

Authors:  Jingwen Li; Yongmin Li; He Liu; Yanlong Liu; Binbin Cui
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.